Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [57]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 293
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Dipeptidyl peptidase IV, a kidney brush-border serine peptidase
Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., & Young, A. R. (1976) · Biochemical Journal · doi:10.1042/bj1570169 · Cited by 254
Cited by
Items 301–400 of 798
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Self-citationAlcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
Jerlhag, E. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146562 · Cited by 53
Aziz, A. A., & Anderson, G. H. (2003) · Journal of Nutrition · doi:10.1093/jn/133.7.2326 · Cited by 58
“(1993) Exendin-4 is a high potency agonist and truncated exendin(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.”
BackgroundMethodInfluentialVollmer, K., Gardiwal, H., Menge, B. A., Goetze, O., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2197 · Cited by 51
“89390), which is specific for the C-terminal end of the GLP-1 molecule and reacts equally with intact GLP-1 and the primary (N-terminally truncated) metabolite as described (28).”
BackgroundSelf-citationArmstrong, M. J., Barton, D., Gaunt, P., Hull, D., Guo, K., Stocken, D., Gough, S. C. L., Tomlinson, J. W., Brown, R. M., Hübscher, S. G., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003995 · Cited by 51
“5–2 min) as it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4).(9) Liraglutide (Victoza) is a long-acting (half-life 13 h) GLP-1 analogue with 97% structural homology to the native hormone and is administered once daily by subcutaneous injection.”
BackgroundIncretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Knop, F. K., Hansen, K. B., & Knop, F. K. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7004 · Cited by 64
“15 While GLP-1 is rapidly degraded (by the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4)) in the circulation with an apparent half-life of 1 to 1.5 minutes, 16 GIP is degraded more slowly, with a half-life for the intact hormone of 7 minutes.”
InfluentialTaspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
Sebokova, E., Christ, A. D., Wang, H., Sewing, S., Dong, J. Z., Taylor, J., Cawthorne, M. A., & Culler, M. D. (2010) · Endocrinology · doi:10.1210/en.2009-1459 · Cited by 51
Porter, D., Faivre, É., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.014 · Cited by 53
Green, B. D., Lavery, K. S., Irwin, N., O’Harte, F. P. M., Harriott, P., Greer, B., Bailey, C. J., & Flatt, P. R. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097824 · Cited by 49
“The duration of action of GLP-1 (t1/2 of 2–3 min) is limited by inactivation due to N-terminal degradation by the enzyme dipeptidyl peptidase IV (DPP IV) (Deacon et al., 1995).”
BackgroundHamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
“However, this approach faced significant challenges that initially hindered the development of GLP-1-based therapies: Endogenous GLP-1 is quickly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4), resulting in a very short half-life of approximately 2 minutes [22].”
BackgroundThe enteroinsular axis in dipeptidyl peptidase IV-negative rats
Pederson, R. A., Kieffer, T. J., Pauly, R. P., Kofod, H., Kwong, J., & McIntosh, C. H. S. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90112-2 · Cited by 60
Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes
Linnebjerg, H., Kothare, P. A., Skrivanek, Z., de la Peña, A., Atkins, M., Ernest, C. S., & Trautmann, M. E. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01800.x · Cited by 48
Derosa, G., Ragonesi, P. D., Carbone, A., Fogari, E., Bianchi, L., Bonaventura, A., Romano, D., Cicero, A. F. G., & Maffioli, P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0278 · Cited by 47
Ketterer, C., Müssig, K., Heni, M., Dudziak, K., Randrianarisoa, E., Wagner, R. J., Machicao, F. E., Stefan, N., Holst, J. J., Fritsche, A., et al. (2011) · Metabolism · doi:10.1016/j.metabol.2011.02.002 · Cited by 53
Self-citationStack, J., Tobin, P. R., Gietl, A., Harnedy, P. A., Stengel, D. B., & Fitzgerald, R. J. (2017) · Journal of Applied Phycology · doi:10.1007/s10811-017-1063-0 · Cited by 54
“Macroalgae”
BackgroundAltered glucose metabolism after bariatric surgery: What's GLP-1 got to do with it?
Smith, E. P., Polanco, G., Yaqub, A., & Salehi, M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.014 · Cited by 54
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Ahrén, B. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12911 · Cited by 48
Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P., Bailey, C., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 46
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Christensen, M., & Knop, F. K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0102-x · Cited by 47
“As mentioned, DPP-4 is responsible for the degradation and inactivation of GLP-1 [2].”
BackgroundÁvila, D. L., de Araújo, G. R., Silva, M., Miranda, P. H. D. A., Diniz, M. F., Pedrosa, M. L., Silva, M. E., de Lima, W. G., & Costa, D. C. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.03.004 · Cited by 47
Ganguli, S., Deleeuw, P., & Satapathy, S. K. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s188991 · Cited by 50
“Native GLP-1 lowers blood glucose by inducing insulin secretion and reducing glucagon secretion.(62,63) GLP-1 receptors have been found on hepatocytes leading to further evaluation in their role on the liver.”
BackgroundZander, M., Madsbad, S., Deacon, C. F., & Holst, J. J. (2005) · Diabetologia · doi:10.1007/s00125-005-0098-y · Cited by 50
“GLP-1 is metabolised by the enzyme dipeptidylpeptidase 4 (DPP-4), generating a truncated metabolite, GLP-1(9–36)-amide [6, 7], which in in vitro studies involving cloned human pancreatic GLP-1 receptors has been shown to bind to the receptor without activating it, suggesting that it may act as an antagonist [8].”
BackgroundSelf-citationPeptide Drug Delivery Strategies for the Treatment of Diabetes
Sadrzadeh, N., Glembourtt, M., & Stevenson, C. L. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20848 · Cited by 49
Cho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.4.262 · Cited by 44
Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect
Hanato, J., Kuriyama, K., Mizumoto, T., Debari, K., Hatanaka, J., Onoue, S., & Yamada, S. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.013 · Cited by 50
“To overcome the drawback of GLP-1, a number of efforts have been made, including development of metabolically stable analogs of GLP-1 (Edwards et al., 2001; Juhl et al., 2002) and DPP-IV inhibitors (Holst and Deacon, 1998).”
InfluentialLotfy, M. A., Singh, J., Kalász, H., Tekes, K., & Adeghate, E. A. (2011) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501105010082 · Cited by 51
Banno, Y., Miyamoto, Y., Sasaki, M., Oi, S., Asakawa, T., Kataoka, O., Takeuchi, K., Suzuki, N., Ikedo, K., Kosaka, T., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.059 · Cited by 46
Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
Neumiller, J. J., & Campbell, R. K. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090555 · Cited by 42
Knop, F. K., Vilsbøll, T., Larsen, S., Madsbad, S., Holst, J. J., & Krarup, T. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2581 · Cited by 44
Self-citationIs there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 49
Self-citationRole of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Sebastián-Martín, A., Sánchez, B. G., Mora-Rodríguez, J. M., Bort, A., & Díaz‐Laviada, I. (2022) · Biomedicines · doi:10.3390/biomedicines10082026 · Cited by 52
“In that case, DPP4-mediated digestion takes place over the already PC1-truncated forms of GLP-1, rendering GLP-19–36amide and GLP-19–37, ligands with low affinity for the GLP-1 receptor [51,52].”
BackgroundDPP-4 Inhibitors in Clinical Practice
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2079 · Cited by 44
“This rapid inactivation of GLP-1 and GIP contributes to a half-life of 2 minutes and 5 to 7 minutes, respectively.(36,41,53,54) This short half-life limits the therapeutic potential of incretins.”
BackgroundDipeptidyl Peptidase- IV Inhibitory Activity of Berberis aristata
Chakrabarti, R., Bhavtaran, S., Narendra, P., Varghese, N., & Thirumurgan, K. (2011) · Cited by 53
O'Harte, F. P. M., Mooney, M. H., Lawlor, A., & Flatt, P. R. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00214-7 · Cited by 48
“The inhibition of His7-glucitol tGLP-1 catabolism would increase the availability of the intact peptide, while also reducing the possible e¡ect of feedback antagonism at the receptor level through a reduction in the formation of the receptor antagonist GLP-1(9^36) amide [23,46,47].”
BackgroundPreliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET
Xu, Q., Zhu, C. Y., Xu, Y., Pan, D., Liu, P., Yang, R., Wang, L., Chen, F., Sun, X., Luo, S., et al. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1020808 · Cited by 44
“1 is limited due to a rapid degradation by dipeptidyl peptidase IV (DPP IV) in vivo [10,11].”
BackgroundCai, H.-Y., Wang, Z., Hölscher, C., Li, Y., Zhang, J., Sun, P., Li, J., Yang, W., Wu, M., & Qi, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.033 · Cited by 47
“However, endogenous GLP-1 is broken down quickly and lasts for only several minutes in blood plasma, which greatly limits its application in clinical practice (Deacon et al., 1995).”
Zhai, H., Li, Z., Peng, M., Huang, Z., Qin, T., Chen, L., Li, H., Zhang, H., Zhang, W., & Xu, G. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.026 · Cited by 47
“GLP-1 circulates as two active forms, GLP-1 (7– 37) andGLP-1 (7–36) amide, andboth of them improve glucose homeostasis and control body weight in experimental models of diabetes and obesity [14,15].”
BackgroundPeptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“Due to the rapid degradation of GLP-1 by DPP-4, GLP-1(9–36) is the most abundant form of GLP-1 in the circulation [189], with some studies”
Self-citationLiu, M.-J., Shin, S., Li, N., Shigihara, T., Lee, Y.-S., Yoon, J., & Jun, H. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300005 · Cited by 44
Flint, A., Kapitza, C., & Zdravkovic, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12108 · Cited by 42
“However, native GLP-1 has a short elimination half-life of 1–2 min [5].”
BackgroundWewer Albrechtsen, N. J., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.051 · Cited by 40
“Moreover, since the predominant circulating form of endogenous GLP-1 is the N-terminally truncated product of DPP-4 action, GLP-1 9-36 NH 2 (Deacon et al., 1995), which may share some effects with GLP-1 (Ban et al., 2008), we also examined the effects of this peptide at relevant doses.”
BackgroundSelf-citationIntestinal mTOR regulates GLP-1 production in mouse L cells
Xu, G., Li, Z., Ding, L., Tang, H. W., Guo, S., Liang, H., Wang, H., & Zhang, W. (2015) · Diabetologia · doi:10.1007/s00125-015-3632-6 · Cited by 41
Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs
Nagell, C. F., Wettergren, A., Ørskov, C., & Holst, J. J. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520500408253 · Cited by 42
“In the circulation, GLP-1 is metabolized by the enzyme dipeptidyl peptidase IV to the N-terminally truncated metabolite GLP-1 9-36amide [28].”
BackgroundSelf-citationGreen, B. D., Gault, V. A., Mooney, M. H., Irwin, N., Harriott, P., Greer, B., Bailey, C. J., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.035 · Cited by 42
“The use of GLP-1 as an antidiabetic agent is significantly curtailed through rapid proteolysis by DPP IV in the cir- culation and results in the formation of the inactive and antagonistic GLP-1(7–36)amide (Mentlein et al., 1993; Deacon et al., 1995; Kieffer et al., 1995).”
InfluentialClinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Adachi, T., Tanaka, T., Takemoto, K., Koshimizu, T., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.162 · Cited by 43
Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
Watkins, J. D., Koumanov, F., & Gonzalez, J. T. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab078 · Cited by 40
Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery
Salehi, M., & D’Alessio, D. A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9291-y · Cited by 40
“Once released to the circulation, GLP-1 is rapidly metabolized by a widely distributed serine protease, dipeptidyl peptidase IV (DPP-4) [55], such that the half-life of bioactive GLP-1 is less than 2 min in humans.”
BackgroundFuruta, S., Smart, C., Hackett, A., Benning, R. K., & Warrington, S. (2012) · Xenobiotica · doi:10.3109/00498254.2012.731618 · Cited by 42
“GLP-1 is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4) (Mentlein et al., 1993; Deacon et al., 1995a, b) with a half-life of plasma active GLP-1 of about 2 min (Vilsbøll et al., 2003).”
Backgroundde Graaf‐Roelfsema, E. (2013) · The Veterinary Journal · doi:10.1016/j.tvjl.2013.09.064 · Cited by 51
“been reported for intact GIP and intact GLP-1, respectively, in humans (Deacon et al., 1995; Meier et al., 2004; Vilsbøll et al., 2006).”
BackgroundThe complexity of signalling mediated by the glucagon-like peptide-1 receptor
Fletcher, M. M., Halls, M. L., Christopoulos, A., Sexton, P. M., & Wootten, D. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150244 · Cited by 39
Stack, J., Le Gouic, A. V., Tobin, P. R., Guihéneuf, F., Stengel, D. B., & FitzGerald, R. J. (2018) · Journal of Food Bioactives · doi:10.31665/jfb.2018.1134 · Cited by 40
Differential regional metabolism of glucagon in anesthetized pigs
Deacon, C. F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M., & Holst, J. J. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00125.2003 · Cited by 40
Self-citationBaggio, L., Adatia, F., Bock, T., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 40
Burgmaier, M., Heinrich, C., & Marx, N. (2013) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03746.x · Cited by 40
Gao, Z., Bai, G., Chen, J., Zhang, Q., Pan, P., Bai, F., & Peng, G. E. N. G. (2009) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.80742 · Cited by 42
Lai, Z., Li, C., Liu, J., Kong, L., Wen, X., & Sun, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.044 · Cited by 39
Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01313.x · Cited by 38
“E-mail: jesse.dong@ipsen.com In vivo, the amide bond linking Ala8 and Glu9 of native GLP-1 is rapidly cleaved by dipeptidylpeptidase-4 (DPP-4) [11], and the peptide has a plasma half-life of only approximately 2 min following intravenous administration [12] and 1 h after subcutaneous administration [13].”
BackgroundInfluentialZhang, B., Yang, B., Zhai, C., Jiang, B., & Wu, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.021 · Cited by 38
Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity
Opinto, G., Natalicchio, A., & Marchetti, P. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.812664 · Cited by 51
“GLP-1 and GIP are rapidly degraded by dipeptidylpeptidase-4 (DPP4) (Deacon et al., 1995a), however, the GLP-1 metabolites may also have specific effects of clinical relevance.”
BackgroundAnalysis of glucagon-like peptide 1; what to measure?
Heijboer, A. C., Frans, A., Lomecky, M. Z., & Blankenstein, M. A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.03.010 · Cited by 47
Rolin, B., Deacon, C. F., Carr, R. D., & Åhrén, B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.05.013 · Cited by 42
Self-citationTrebbien, R., Klarskov, L., Olesen, M., Holst, J. J., Carr, R. D., & Deacon, C. F. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00353.2003 · Cited by 44
“Products of the proglucagon (PG) gene [glucagon and glucagon-like peptide 1 (GLP-1)] were shown to be relatively good substrates, whereas the structurally related peptide glucose-dependent insulinotropic polypeptide (GIP) was somewhat less susceptible.”
MethodSelf-citationDiscovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors
Qiao, L., Baumann, C. A., Crysler, C. S., Ninan, N. S., Abad, M. C., Spurlino, J. C., DesJarlais, R. L., Kervinen, J., Neeper, M. P., Bayoumy, S. S., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.037 · Cited by 38
A Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination
Garcin, C. L., & Habib, S. J. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-53150-2_15 · Cited by 43
Wang, T., Gou, Z., Wang, F., Ma, M., & Zhai, S.-D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103798 · Cited by 37
“physiological levels of GLP-1 [9].”
The gut-brain axis: a major glucoregulatory player
Burcelin, R. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70468-7 · Cited by 40
The effects of GLP-1 infusion in the hepatic portal region on food intake
Kim, D.-H., D'Alessio, D. A., Woods, S. C., & Seeley, R. J. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.03.002 · Cited by 37
“After secretion into the circulation, GLP-1 is rapidly degraded by a dipeptidyl peptidase IV, which is widely expressed on capillary endothelial cells most prominently in the liver, lung and kidney [3,4].”
Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll, T., Toft-Nielsen, M. B., Krarup, T., Madsbad, S., Dinesen, B., & Holst, J. J. (2000) · Diabetes Care · doi:10.2337/diacare.23.6.807 · Cited by 37
Self-citationO'Harte, F. P. M., Gray, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (1997) · Peptides · doi:10.1016/s0196-9781(97)00201-5 · Cited by 37
Kapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0044-y · Cited by 36
Li, N., Lu, J., & Willars, G. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047936 · Cited by 35
“major circulating form of GLP-1 in the fed state [36-38].”
BackgroundA Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans
Nissen, A. A., Marstrand, S. D., Skov‐Jeppesen, K., Bremholm, L., Hornum, M., Andersen, U. B., Holst, J. J., ROSENKILDE, M. M., & Hartmann, B. (2019) · JBMR Plus · doi:10.1002/jbm4.10209 · Cited by 36
“Active GLP‐1, GLP‐1 (7‐36)amide, has an apparent plasma half‐life of approximately 2 min, as it is rapidly degraded to GLP‐1 (9‐36)amide by the enzyme, dipeptidyl peptidase‐4 (DPP‐4).((2))”
BackgroundSelf-citationHuang, J., Liu, Y., Cheng, L., Li, J., Zhang, T., Zhao, G., & Zhang, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173581 · Cited by 36
New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on Incretins
Gallwitz, B. (2005) · The Review of Diabetic Studies · doi:10.1900/rds.2005.2.61 · Cited by 44
“Only 20% of the GLP-1 administered during a continuous intravenous infusion is estimated to reach circulation intact as the active form [24, 39].”
BackgroundKim, K.-R., Rhee, S.-D., Kim, H. Y., Jung, W. H., Yang, S., Kim, S. S., Ahn, J. H., & Cheon, H. G. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.030 · Cited by 36
Chapter 19. DPP-IV inhibition and therapeutic potential
Villhauer, E. B., Coppola, G. M., & Hughes, T. E. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36059-1 · Cited by 38
Yue, X., Yan, X., Wu, C., Niu, G., Ma, Y., Jacobson, O., Shen, B., Kiesewetter, D. O., & Chen, X. S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5001857 · Cited by 35
Evidence for the existence and potential roles of intra-islet glucagon-like peptide-1
Campbell, S. A., Johnson, J., & Light, P. E. (2021) · Islets · doi:10.1080/19382014.2021.1889941 · Cited by 42
“Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide,pep-”
BackgroundInfluentialImplementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors
Holst, J. J. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_33 · Cited by 40
Self-citationHarnessing the Therapeutic Potential of Glucagon-Like Peptide-1: A Critical Review
Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 36
“[100,101] In both healthy individuals and those with diabetes mellitus, intravenous or subcutaneous GLP-1 is rapidly degraded (within 30 minutes) to GLP-1(9-36)NH2, which accounts for the majority of circulating immunoreactive GLP-1.”
BackgroundPridal, L., Deacon, C. F., Kirk, O., Christensen, J. V., Carr, R. D., & Holst, J. J. (1996) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190278 · Cited by 35
Self-citationSharma, R., McDonald, T. S., Eng, H. F., Limberakis, C., Stevens, B. D., Patel, S., & Kalgutkar, A. S. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054254 · Cited by 36
Targets and probes for non-invasive imaging of β-cells
Jodal, A., Schibli, R., & Béhé, M. P. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3592-1 · Cited by 36
“The endogenous peptide GLP-1, however, has a very short plasma half-life, as it is rapidly metabolized by dipeptidyl peptidase-4 (DPP4), making it unsuitable as a tracer [33, 108].”
BackgroundO'Harte, F. P. M., Abdel‐Wahab, Y. H. A., Conlon, J. M., & Flatt, P. R. (1998) · Diabetologia · doi:10.1007/s001250051050 · Cited by 35
“This enzyme gives rise to GLP-1(9‐36)amide [41, 44 ] which exhibits a substantial decrease in insulinotropic activity [45, 46].”
BackgroundGlucagon-like Peptide-1 Plasmid Construction and Delivery for the Treatment of Type 2 Diabetes
Choi, S., Oh, S., Lee, M., & Kim, S. W. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.039 · Cited by 35
Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018)
Hussain, H., Abbas, G., Green, I. R., & Ali, I. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1632290 · Cited by 37
“The extracellular domain is responsible for ligand binding and for DPP-4 activity [5,6].”
BackgroundCan dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Cheng, Q., Cheng, J., Cordato, D. J., & Gao, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107559 · Cited by 33
Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., & Mallo, F. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2021.12.005 · Cited by 35
The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
Qiu, Y., Fu, B., Luo, D., Wang, H., Cao, H., Chen, X., Tian, L., & Yu, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.856954 · Cited by 35
Sakashita, H., Kitajima, H., Nakamura, M., Akahoshi, F., & Hayashi, Y. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.077 · Cited by 33
Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors
Li, Q., Li, H., Zhang, B., Zhou, J., & Zhang, H. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01818a · Cited by 34
Inhibition of Human Gastric Lipase Secretion by Glucagon-like Peptide-1
Wøjdemann, M., Wettergren, A., Sternby, B., Holst, J. J., Larsen, S., Rehfeld, J. F., & Olsen, O. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018874300026 · Cited by 39
“The antibody has an absolute requirement for the amidated C-terminus of the molecule for binding and therefore measures the sum of GLP-1 7± 36 amide and its ® rst metabolite, GLP-1 9 ± 36 amide (14) .”
BackgroundSelf-citationSchou, J. H., Pilgaard, K. A., Vilsbøll, T., Jensen, C. B., Deacon, C. F., Holst, J. J., Vølund, A., Madsbad, S., & Vaag, A. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0382 · Cited by 34
“The use of this assay rather than an NH-terminal assay measuring only the intact, biologically active GLP-1 is essential to estimate the rate of secretion of GLP-1 because the hormone is metabolized intravascularly and extremely rapidly (with an apparent half-life of 1–15 min and a clearance rate exceeding cardiac out…”
MethodSelf-citationDou, W., Lei, J.-Y., Lian-fen, Z., Xu, Z., Chen, Y., & Jin, J. (2008) · Protein Expression and Purification · doi:10.1016/j.pep.2008.04.012 · Cited by 32
Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 38
“GLP-1 receptor agonists, as the approved pharmaceuticals liraglutide, exenatide, lixinatide, albiglutide and dulaglutide are designed to be more resistant to degradation than endogenous GLP-1 that with a half-life of less than two minutes has little therapeutic potential [6].”
BackgroundK579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent
Takasaki, K., Iwase, M., Nakajima, T., Ueno, K., Nomoto, Y., Nakanishi, S., & Higo, K. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.12.029 · Cited by 33
Sakashita, H., Akahoshi, F., Kitajima, H., Tsutsumiuchi, R., & Hayashi, Y. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.01.022 · Cited by 31
Targeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 35
Self-citation
Metadata
- Authors
- Deacon, C. F., Johnsen, A. H., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-03
- Volume
- 80
- Issue
- 3
- Pages
- 952-957
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068183831
- Cited by
- 792
- References
- 28
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 24 · 2023: 10 · 2022: 14 · 2021: 24 · 2020: 18 · 2019: 34 · 2018: 25 · 2017: 37 · 2016: 41 · 2015: 22 · 2014: 27 · 2013: 40 · 2012: 42
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- glucagon-like peptide-1, dipeptidyl peptidase IV, human plasma, peptide metabolism, endogenous metabolites
- MeSH terms
- Chromatography, High Pressure Liquid, Female, Glucagon, Humans, Male, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.